| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the MRC Cyclotron Unit (Drs. Turjanski and Brooks), Hammersmith Hospital, and the Institute of Neurology (Drs. Lees and Brooks), London, UK.
Address correspondence and reprint requests to Dr. Nora Turjanski, MRC Cyclotron Unit, Hammersmith Hospital, Du Cane Road, London W12 OHS, UK.
Dyskinesias are usually seen in Parkinson's disease (PD) patients after several years of L-dopa therapy. Their presence has been attributed to supersensitivity of striatal D1 and D2 receptors. We have used PET to assess striatal D2 receptor binding in untreated PD patients and striatal D1 and D2 binding in L-dopa-treated PD patients. Untreated patients showed a 14% increase in mean D2 receptor binding in the putamen contralateral to the more affected limbs(p < 0.02). Treated patients were segregated into subgroups according to the presence or absence of dyskinesias. There were no differences in mean caudate and putamen D1 and D2 binding between dyskinetic and nondyskinetic patients, matched for duration of clinical disease. Both dyskinetic and nondyskinetic PD subgroups showed a similar 16% reduction of mean caudate D2 binding (p < 0.01) with normal D2 binding in putamen. Mean caudate and putamen D1 binding potentials of both subgroups were reduced by 10% compared with those of controls, though this trend did not reach significance. Putamen D1 binding, however, showed a negative correlation with duration of disease and L-dopa treatment (p < 0.03). These findings suggest that, while exposure of PD patients to L-dopa may be associated with reductions in caudate D2 and caudate and putamen D1 receptor, dyskinesias are unlikely to result from alterations in striatal dopamine receptor binding.
Received December 24, 1996. Accepted in final form April 11, 1997.
This article has been cited by other articles:
|
|
 |
|
  J. Brotchie and C. Fitzer-Attas Mechanisms compensating for dopamine loss in early Parkinson disease Neurology, February 17, 2009; 72(7_Supplement_2): S32 - S38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Rascol, W. Poewe, A. Lees, M. Aristin, L. Salin, N. Juhel, L. Waldhauser, T. Schindler, and for the ADVANS Study Group Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations: The ADVANS Study Arch Neurol, May 1, 2008; 65(5): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Drew, E. H. Simpson, C. Kellendonk, W. G. Herzberg, O. Lipatova, S. Fairhurst, E. R. Kandel, C. Malapani, and P. D. Balsam Transient Overexpression of Striatal D2 Receptors Impairs Operant Motivation and Interval Timing J. Neurosci., July 18, 2007; 27(29): 7731 - 7739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de la Fuente-Fernandez, V. Sossi, Z. Huang, S. Furtado, J.-Q. Lu, D. B. Calne, T. J. Ruth, and A. J. Stoessl Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain, December 1, 2004; 127(12): 2747 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Colloby and J. O'Brien Functional Imaging in Parkinson's Disease and Dementia with Lewy Bodies J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 158 - 163. [Abstract] [PDF]
|
|
|
|
|
|
J.-C. Corvol, M.-P. Muriel, E. Valjent, J. Feger, N. Hanoun, J.-A. Girault, E. C. Hirsch, and D. Herve Persistent Increase in Olfactory Type G-Protein {alpha} Subunit Levels May Underlie D1 Receptor Functional Hypersensitivity in Parkinson Disease J. Neurosci., August 4, 2004; 24(31): 7007 - 7014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Manson, A. Schrag, and A. J. Lees Low-dose olanzapine for levodopa induced dyskinesias Neurology, September 26, 2000; 55(6): 795 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Piccini, D. J Brooks, K. Korpela, N. Pavese, M. Karlsson, and A. Gordin The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, May 1, 2000; 68(5): 589 - 594. [Abstract] [Full Text]
|
|
|
|
|
|
V. Kaasinen, K. Nagren, J. Hietala, V. Oikonen, H. Vilkman, L. Farde, C. Halldin, and J. O. Rinne Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease Neurology, April 11, 2000; 54(7): 1482 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Oliveri, G. Annesi, M. Zappia, D. Civitelli, R. Montesanti, D. Branca, G. Nicoletti, P. Spadafora, A. A. Pasqua, R. Cittadella, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD Neurology, October 22, 1999; 53(7): 1425 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Piggott, E. F. Marshall, N. Thomas, S. Lloyd, J. A. Court, E. Jaros, D. Burn, M. Johnson, R. H. Perry, I. G. McKeith, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution Brain, August 1, 1999; 122(8): 1449 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Turjanski, A. J. Lees, and D. J. Brooks Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies Neurology, March 1, 1999; 52(5): 932 - 932. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
